​

Apellis Pharmaceuticals (APLS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

APLS Stock Forecast

Apellis Pharmaceuticals stock forecast is as follows: an average price target of $70.80 (represents a 113.70% upside from APLS’s last price of $33.13) and a rating consensus of 'Buy', based on 16 wall street analysts offering a 1-year stock forecast.

APLS Price Target

The average price target for Apellis Pharmaceuticals (APLS) is $70.80 based on 1-year price targets from 16 Wall Street analysts in the past 3 months, with a price target range of $92.00 to $39.00. This represents a potential 113.70% upside from APLS's last price of $33.13.

APLS Analyst Ratings

Buy

According to 16 Wall Street analysts, Apellis Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for APLS stock is 1 'Strong Buy' (6.25%), 12 'Buy' (75.00%), 3 'Hold' (18.75%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Apellis Pharmaceuticals Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 06, 2024Douglas TsaoH.C. Wainwright$57.00$27.01111.03%72.05%
Sep 23, 2024Colleen KusyRobert W. Baird$92.00$31.75189.79%177.69%
Sep 20, 2024Annabel SamimyStifel Nicolaus$84.00$31.68165.15%153.55%
Sep 20, 2024Graig SuvannavejhMizuho Securities$39.00$36.736.18%17.72%
Sep 16, 2024Graig SuvannavejhMizuho Securities$42.00$37.6211.64%26.77%
Aug 09, 2024Colleen KusyRobert W. Baird$96.00$37.66154.91%189.77%
Aug 08, 2024Akash TewariJefferies$82.00$37.66117.74%147.51%
Aug 02, 2024Douglas TsaoH.C. Wainwright$83.00$36.00130.56%150.53%
Jul 26, 2024Colleen KusyRobert W. Baird$86.00$38.88121.19%159.58%
Jul 01, 2024Graig SuvannavejhMizuho Securities$49.00$38.3627.74%47.90%
May 23, 2024Derek ArchilaWells Fargo$48.00$43.6010.09%44.88%
Feb 05, 2024Akash TewariJefferies$80.00$68.1617.37%141.47%
Jan 02, 2023Derek ArchilaWells Fargo$58.00$51.7112.16%75.07%
Nov 15, 2022J.P. Morgan$79.00$46.6169.49%138.45%
Sep 12, 2022Wedbush$67.00$67.07-0.10%102.23%
Sep 08, 2022Stifel Nicolaus$65.00$65.38-0.58%96.20%
Aug 18, 2022Oppenheimer$78.00$65.5019.08%135.44%
Aug 09, 2022Credit Suisse$52.00$63.58-18.21%56.96%
Aug 09, 2022Goldman Sachs$102.00$62.3363.65%207.88%
Aug 09, 2022Raymond James$113.00$62.3381.29%241.08%
Jul 20, 2022Citigroup$86.00$52.0665.19%159.58%
Jun 23, 2022Annabel SamimyStifel Nicolaus$60.00$44.5334.74%81.10%
May 24, 2022Goldman Sachs$84.00$44.4289.10%153.55%
May 05, 2022Credit Suisse$44.00$45.33-2.93%32.81%
May 05, 2022Raymond James$102.00$47.54114.56%207.88%
Nov 09, 2021Matthew LuchiniBMO Capital$69.00$37.3484.79%108.27%
Nov 09, 2021Laura ChicoWedbush$28.00$37.34-25.01%-15.48%
Oct 01, 2021Chris HowertonJefferies$74.00$33.59120.30%123.36%
Oct 01, 2021Alethia YoungCantor Fitzgerald$74.00$33.59120.30%123.36%
Sep 10, 2021Tiago FauthCredit Suisse$38.00$34.938.79%14.70%
Jul 01, 2021Phil NadeauCowen & Co.$70.00$67.803.24%111.29%

The latest Apellis Pharmaceuticals stock forecast, released on Nov 06, 2024 by Douglas Tsao from H.C. Wainwright, set a price target of $57.00, which represents a 111.03% increase from the stock price at the time of the forecast ($27.01), and a 72.05% increase from APLS last price ($33.13).

Apellis Pharmaceuticals Price Target by Period

1M3M12M
# Anlaysts-412
Avg Price Target-$68.00$69.83
Last Closing Price$33.13$33.13$33.13
Upside/Downside-100.00%105.25%110.78%

In the current month, the average price target of Apellis Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Apellis Pharmaceuticals's last price of $33.13. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Nov 05, 2024Bank of America SecuritiesBuyBuyHold
Oct 16, 2024Wells FargoSector PerformSector PerformHold
Oct 16, 2024William BlairOutperformInitialise
Sep 22, 2024CitigroupBuyBuyHold
Sep 13, 2024WedbushBuyBuyHold
Sep 13, 2024UBSUnderperformUnderperformHold
Aug 09, 2024WedbushNeutralNeutralHold
Aug 08, 2024Goldman SachsBuyBuyHold
Aug 02, 2024UBSUnderperformUnderperformHold
Aug 02, 2024Wells FargoBuyBuyHold
Aug 02, 2024H.C. WainwrightBuyBuyHold
Jul 31, 2024JefferiesBuyBuyHold
Jul 22, 2024CitigroupBuyBuyHold
Jun 28, 2024WedbushUnderperformUnderperformHold
Jun 28, 2024Wells FargoBuyBuyHold
May 31, 2024Piper SandlerNeutralInitialise
May 28, 2024Wells FargoBuyBuyHold
May 28, 2024WedbushUnderperformUnderperformHold
May 24, 2024UBSBuyBuyHold
May 23, 2024Wells FargoEqual-WeightEqual-WeightHold
May 14, 2024Cowen & Co.BuyBuyHold
Mar 27, 2024WedbushBuyBuyHold
Mar 27, 2024UBSUnderperformUnderperformHold
Feb 28, 2024Wells FargoBuyBuyHold
Feb 28, 2024WedbushUnderperformUnderperformHold
Feb 28, 2024WedbushNeutralNeutralHold
Feb 05, 2024JefferiesBuyUpgrade
Jan 24, 2024NeedhamBuyBuyHold
Jan 17, 2024BarclaysBuyBuyHold
Dec 15, 2023OppenheimerOutperformOutperformHold
Dec 04, 2023Bank of America SecuritiesBuyUpgrade
Oct 06, 2023HSBCOverweightUpgrade
Sep 15, 2023Wells FargoEqual-WeightOverweightUpgrade
May 05, 2023NeedhamBuyBuyHold
Apr 17, 2023WedbushNeutralNeutralHold
Jan 03, 2023Wells FargoEqual-WeightDowngrade
Sep 12, 2022WedbushNeutralNeutralHold
Aug 18, 2022OppenheimerOutperformOutperformHold
Aug 09, 2022Credit SuisseNeutralNeutralHold
Aug 09, 2022Goldman SachsBuyBuyHold
Aug 09, 2022Raymond JamesStrong BuyStrong BuyHold
Jul 20, 2022CitigroupBuyBuyHold
May 24, 2022Goldman SachsBuyBuyHold

Apellis Pharmaceuticals's last stock rating was published by Bank of America Securities on Nov 05, 2024. The company gave APLS a "Buy" rating, the same as its previous rate.

Apellis Pharmaceuticals Financial Forecast

Apellis Pharmaceuticals Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20
Revenue-------------$99.18M$89.64M$44.85M$22.66M$22.06M$16.32M$14.38M$60.29M$5.65M$623.00K-$250.00M
Avg Forecast$279.88M$263.57M$250.02M$234.11M$226.42M$211.37M$203.64M$194.37M$193.85M$200.00M$190.89M$163.27M$143.34M$99.05M$70.24M$26.11M$24.41M$21.59M$16.95M$12.57M$8.79M$7.23M$500.10K$2.50M$109.83M
High Forecast$302.45M$284.83M$270.18M$252.99M$244.68M$228.42M$220.07M$211.49M$204.41M$202.28M$190.89M$163.32M$149.09M$99.22M$75.91M$28.21M$26.38M$21.59M$16.95M$12.57M$8.79M$7.23M$500.10K$2.50M$109.83M
Low Forecast$248.91M$234.41M$222.36M$208.21M$201.37M$187.98M$181.11M$172.97M$184.56M$197.72M$190.89M$163.21M$139.14M$98.89M$62.47M$23.22M$21.71M$21.59M$16.95M$12.57M$8.79M$7.23M$500.10K$2.50M$109.83M
# Analysts644643791496612999555566669
Surprise %-------------1.00%1.28%1.72%0.93%1.02%0.96%1.14%6.86%0.78%1.25%-2.28%

Apellis Pharmaceuticals's average Quarter revenue forecast for Dec 23 based on 12 analysts is $143.34M, with a low forecast of $139.14M, and a high forecast of $149.09M. APLS's average Quarter revenue forecast represents a 44.52% increase compared to the company's last Quarter revenue of $99.18M (Sep 23).

Apellis Pharmaceuticals EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20
# Analysts644643791496612999555566669
EBITDA-------------$-148.30M$-125.77M$-169.57M$-159.30M$-149.67M$-146.70M$-128.83M$-144.19M$-193.01M$-214.98M$-179.09M$87.93M
Avg Forecast$-167.93M$-158.14M$-150.01M$-140.46M$-135.85M$-126.82M$-122.19M$-116.62M$-116.31M$-120.00M$-114.53M$-144.07M$-86.01M$-59.43M$-42.15M$-130.98M$-151.40M$-12.24M$-9.61M$-119.07M$-4.98M$-4.10M$-283.61K$-76.54M$-62.28M
High Forecast$-149.35M$-140.65M$-133.41M$-124.92M$-120.82M$-112.79M$-108.67M$-103.78M$-110.74M$-118.63M$-114.53M$-115.26M$-83.49M$-59.34M$-37.48M$-104.78M$-121.12M$-12.24M$-9.61M$-95.26M$-4.98M$-4.10M$-283.61K$-61.23M$-62.28M
Low Forecast$-181.47M$-170.90M$-162.11M$-151.79M$-146.81M$-137.05M$-132.04M$-126.89M$-122.65M$-121.37M$-114.53M$-172.89M$-89.45M$-59.53M$-45.54M$-157.17M$-181.68M$-12.24M$-9.61M$-142.88M$-4.98M$-4.10M$-283.61K$-91.84M$-62.28M
Surprise %-------------2.50%2.98%1.29%1.05%12.22%15.27%1.08%28.94%47.10%758.00%2.34%-1.41%

6 analysts predict APLS's average Quarter EBITDA for Mar 21 to be $-76.54M, with a high of $-61.23M and a low of $-91.84M. This is -187.04% lower than Apellis Pharmaceuticals's previous annual EBITDA (Dec 20) of $87.93M.

Apellis Pharmaceuticals Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20
# Analysts644643791496612999555566669
Net Income-------------$-140.24M$-122.04M$-177.78M$-165.99M$-191.27M$-155.98M$-138.94M$-147.93M$-195.57M$-219.19M$-183.66M$78.27M
Avg Forecast$24.29M$13.05M$3.67M$-8.54M$-17.38M$-36.40M$-37.41M$-42.91M$-46.28M$-36.54M$-37.94M$-155.38M$-90.54M$-123.10M$-168.48M$-141.25M$-155.33M$-181.32M$-175.24M$-128.41M$-190.58M$-209.84M$-212.68M$-114.73M$-82.58M
High Forecast$26.84M$14.41M$4.05M$-7.31M$-14.88M$-31.17M$-32.03M$-30.35M$-37.67M$-31.29M$-32.49M$-124.30M$-6.86M$-105.39M$-144.24M$-113.00M$-124.26M$-181.32M$-175.24M$-102.73M$-190.58M$-209.84M$-212.68M$-91.78M$-82.58M
Low Forecast$20.80M$11.17M$3.14M$-9.43M$-19.20M$-40.22M$-41.34M$-58.60M$-73.18M$-40.38M$-41.92M$-186.45M$-139.93M$-136.00M$-186.14M$-169.50M$-186.40M$-181.32M$-175.24M$-154.09M$-190.58M$-209.84M$-212.68M$-137.68M$-82.58M
Surprise %-------------1.14%0.72%1.26%1.07%1.05%0.89%1.08%0.78%0.93%1.03%1.60%-0.95%

Apellis Pharmaceuticals's average Quarter net income forecast for Mar 21 is $-114.73M, with a range of $-137.68M to $-91.78M. APLS's average Quarter net income forecast represents a -246.59% decrease compared to the company's last Quarter net income of $78.27M (Dec 20).

Apellis Pharmaceuticals SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20
# Analysts644643791496612999555566669
SG&A-------------$145.65M$111.37M$102.09M$84.37M$78.41M$63.20M$51.19M$41.46M$45.76M$48.97M$40.58M$44.49M
Avg Forecast$512.15M$482.31M$457.51M$428.39M$414.33M$386.79M$372.64M$355.67M$354.72M$365.98M$349.31M$57.24M$262.30M$181.26M$128.54M$47.77M$44.67M$39.49M$30.99M$23.00M$16.07M$13.22M$914.70K$4.57M$200.88M
High Forecast$553.45M$521.21M$494.41M$462.94M$447.74M$417.98M$402.70M$387.00M$374.05M$370.15M$349.31M$68.69M$272.82M$181.55M$138.90M$51.63M$48.27M$39.49M$30.99M$23.00M$16.07M$13.22M$914.70K$4.57M$200.88M
Low Forecast$455.48M$428.95M$406.89M$380.99M$368.49M$343.99M$331.41M$316.52M$337.72M$361.81M$349.31M$45.80M$254.62M$180.97M$114.32M$42.49M$39.73M$39.49M$30.99M$23.00M$16.07M$13.22M$914.70K$4.57M$200.88M
Surprise %-------------0.80%0.87%2.14%1.89%1.99%2.04%2.23%2.58%3.46%53.53%8.87%0.22%

Apellis Pharmaceuticals's average Quarter SG&A projection for Dec 23 is $262.30M, based on 12 Wall Street analysts, with a range of $254.62M to $272.82M. The forecast indicates a 80.09% rise compared to APLS last annual SG&A of $145.65M (Sep 23).

Apellis Pharmaceuticals EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20
# Analysts644643791496612999555566669
EPS-------------$-1.17$-1.02$-1.56$-1.52$-1.75$-1.46$-1.42$-1.73$-2.28$-2.72$-2.32$0.99
Avg Forecast$0.20$0.11$0.03$-0.07$-0.14$-0.29$-0.30$-0.35$-0.37$-0.29$-0.31$-0.48$-0.73$-0.99$-1.36$-1.48$-1.52$-1.46$-1.41$-1.33$-1.54$-1.69$-1.72$-1.64$-0.67
High Forecast$0.22$0.12$0.03$-0.06$-0.12$-0.25$-0.26$-0.24$-0.30$-0.25$-0.26$-0.41$-0.06$-0.85$-1.16$-1.27$-1.30$-1.46$-1.41$-1.33$-1.54$-1.69$-1.72$-1.64$-0.67
Low Forecast$0.17$0.09$0.03$-0.08$-0.15$-0.32$-0.33$-0.47$-0.59$-0.33$-0.34$-0.53$-1.13$-1.10$-1.50$-1.63$-1.68$-1.46$-1.41$-1.33$-1.54$-1.69$-1.72$-1.64$-0.67
Surprise %-------------1.18%0.75%1.06%1.00%1.20%1.03%1.06%1.12%1.35%1.58%1.42%-1.49%

According to 6 Wall Street analysts, Apellis Pharmaceuticals's projected average Quarter EPS for Mar 21 is $-1.64, with a low estimate of $-1.64 and a high estimate of $-1.64. This represents a -265.31% decrease compared to APLS previous annual EPS of $0.99 (Dec 20).

Apellis Pharmaceuticals Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
INZYInozyme Pharma$2.94$16.00444.22%Buy
XFORX4 Pharmaceuticals$0.74$3.67395.95%Buy
ABOSAcumen Pharmaceuticals$1.96$7.00257.14%Buy
TERNTerns Pharmaceuticals$6.80$18.67174.56%Buy
MREOMereo BioPharma Group$3.40$8.00135.29%Buy
APLSApellis Pharmaceuticals$34.53$70.80105.04%Buy
AMLXAmylyx Pharmaceuticals$4.28$8.2592.76%Buy
DAWNDay One Biopharmaceuticals$12.64$24.0089.87%Buy
IMVTImmunovant$27.91$51.0082.73%Buy
AKROAkero Therapeutics$30.61$50.0063.35%Buy
BPMCBlueprint Medicines$96.48$122.6027.07%Buy
MDGLMadrigal Pharmaceuticals$306.08$315.753.16%Buy

APLS Forecast FAQ

Is Apellis Pharmaceuticals a good buy?

Yes, according to 16 Wall Street analysts, Apellis Pharmaceuticals (APLS) is considered a 'Buy'. The rating consensus is based on 1 'Strong Buy' and 12 'Buy' recommendations, accounting for 81.25% of APLS's total ratings.

What is APLS's price target?

Apellis Pharmaceuticals (APLS) average price target is $70.8 with a range of $39 to $92, implying a 113.70% from its last price of $33.13. The data is based on 16 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Apellis Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for APLS stock, the company can go up by 113.70% (from the last price of $33.13 to the average price target of $70.8), up by 177.69% based on the highest stock price target, and up by 17.72% based on the lowest stock price target.

Can Apellis Pharmaceuticals stock reach $50?

APLS's average twelve months analyst stock price target of $70.8 supports the claim that Apellis Pharmaceuticals can reach $50 in the near future.

What are Apellis Pharmaceuticals's analysts' financial forecasts?

Apellis Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $835.8M (high $904.66M, low $743.44M), average EBITDA is $-501M (high $-446M, low $-543M), average net income is $-134M (high $-108M, low $-159M), average SG&A $1.53B (high $1.66B, low $1.36B), and average EPS is $-1.082 (high $-0.875, low $-1.286). APLS's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $1.03B (high $1.11B, low $913.88M), average EBITDA is $-617M (high $-548M, low $-666M), average net income is $32.47M (high $38M, low $25.68M), average SG&A $1.88B (high $2.03B, low $1.67B), and average EPS is $0.262 (high $0.307, low $0.207).

Did the APLS's actual financial results beat the analysts' financial forecasts?

Based on Apellis Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $366.28M, beating the average analysts forecast of $338.75M by 8.13%. Apple's EBITDA was $-547M, beating the average prediction of $-319M by 71.85%. The company's net income was $-529M, beating the average estimation of $-523M by 1.01%. Apple's SG&A was $500.82M, missing the average forecast of $619.87M by -19.21%. Lastly, the company's EPS was $-4.45, missing the average prediction of $-4.562 by -2.46%. In terms of the last quarterly report (Sep 2023), Apellis Pharmaceuticals's revenue was $99.18M, beating the average analysts' forecast of $99.05M by 0.13%. The company's EBITDA was $-148M, beating the average prediction of $-59.433M by 149.52%. Apellis Pharmaceuticals's net income was $-140M, beating the average estimation of $-123M by 13.92%. The company's SG&A was $145.65M, missing the average forecast of $181.26M by -19.65%. Lastly, the company's EPS was $-1.17, beating the average prediction of $-0.993 by 17.77%